6-(3,4-difluorophenyl)-3,4-dihydronaphthalen-1(2H)-one | 929643-09-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-(3,4-difluorophenyl)-3,4-dihydronaphthalen-1(2H)-one
• 英文别名: 6-(3,4-difluorophenyl)-3,4-dihydro-2H-naphthalen-1-one
• CAS: 929643-09-4
• 化学式: C₁₆H₁₂F₂O
• 分子量: 258.267
• InChiKey: MQAZZGFNVGTTLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(3,4-difluorophenyl)-3,4-dihydronaphthalen-1(2H)-one 、 4-溴吡啶 在 正丁基锂 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 为溶剂， 以40%的产率得到6-(3,4-difluorophenyl)-1-(pyridin-4-yl)-1,2,3,4-tetrahydronaphthalen-1-ol
  参考文献：
  名称：

  Synthesis, Biological Evaluation, and Molecular Modeling of Abiraterone Analogues: Novel CYP17 Inhibitors for the Treatment of Prostate Cancer

  摘要：

  Abiraterone, a steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer. Since steroidal compounds often show side effects attributable to their structure, we have tried to replace the sterane scaffold by nonsteroidal core structures. The design and synthesis of 20 new abiraterone mimetics are described. Their activities have been tested with recombinant human CYP17 expressed in E. coli. Promising compounds were further evaluated for selectivity against CYP11B1, CYP11B2, and the hepatic CYP3A4. Compounds 19 and 20 showed comparable activity to abiraterone (IC50 values of 144 and 64 nM vs 72 nM) and similar or even better selectivity against the other CYP enzymes. Selected compounds were also docked into our homology model, and the same binding modes as for abiraterone were found.

  DOI：

  10.1021/jm800355c
• 作为产物：
  描述：

  5-氧代-5,6,7,8-四氢萘-2-基 三氟甲烷磺酸 、 3,4-二氟苯硼酸 生成 6-(3,4-difluorophenyl)-3,4-dihydronaphthalen-1(2H)-one
  参考文献：
  名称：

  5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators

  摘要：

  提供了公式I或II的化合物，其中R1-R8在此定义，以及包含这些化合物的药物组合物和工具包。还提供了使用公式I、公式II或公式III的化合物诱导避孕、提供激素替代疗法、治疗周期相关症状或治疗或预防良性或恶性肿瘤疾病的方法，其中R1-R9在此定义：

  公开号：

  US07319152B2

文献信息

• 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
  申请人：Zhang Puwen

  公开号：US20070066628A1

  公开（公告）日：2007-03-22

  Compounds of formula I are provided, wherein R 1 -R 9 and n are defined herein, and pharmaceutical compositions and kits containing these compounds. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I or formula II, wherein R 3 -R 5 , R 10 , and R 11 are defined herein.

  提供了式I的化合物，其中R1-R9和n在此处定义，并且含有这些化合物的药物组合物和试剂盒。 还提供了使用式I或式II的化合物诱导避孕、提供激素替代疗法、治疗与周期相关的症状，或治疗或预防良性或恶性肿瘤疾病的方法，其中R3-R5、R10和R11在此处定义。
• 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
  申请人：Zhang Puwen

  公开号：US20070066675A1

  公开（公告）日：2007-03-22

  Compounds of formula I or II are provided, wherein R 1 —R 8 are defined herein, and pharmaceutical compositions and kits containing these compounds. Also provides are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I, formula II, or formula III, wherein R 2 —R 4 and R 9 are defined herein.

  提供了式I或II的化合物，其中R1至R8在此处定义，并含有这些化合物的药物组合物和试剂盒。 还提供了使用式I、式II或式III的化合物诱导避孕、提供激素替代疗法、治疗与周期相关的症状，或治疗或预防良性或恶性肿瘤疾病的方法，其中R2至R4和R9在此处定义。
• 5-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS
  申请人：Zhang Puwen

  公开号：US20090325916A1

  公开（公告）日：2009-12-31

  Compounds of formula I or II and pharmaceutical compositions and kits containing these compounds are provided. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I, formula II, or formula III.

  提供化学式I或II的化合物，以及含有这些化合物的药物组合物和工具箱。同时，提供使用化学式I、化学式II或化学式III的化合物诱导避孕、提供激素替代疗法、治疗与周期相关的症状，或治疗或预防良性或恶性肿瘤疾病的方法。
• 5-Aryl indan-1 one and analogs useful as progesterone receptor modulators
  申请人：Zhang Puwen

  公开号：US20080119537A1

  公开（公告）日：2008-05-22

  Compounds of formula I or II and pharmaceutical compositions and kits containing these compounds are provided. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I, formula II, or formula III.

  本发明提供了化学式I或II的化合物以及含有这些化合物的药物组合物和试剂盒。还提供了使用化学式I、化学式II或化学式III的化合物诱导避孕、提供激素替代疗法、治疗与月经周期相关的症状或治疗或预防良性或恶性肿瘤的方法。
• US7319152B2
  申请人：——

  公开号：US7319152B2

  公开（公告）日：2008-01-15